Citi analyst Robyn Karnauskas views the post-earnings pullback in shares of Tesaro as a buying opportunity. While Zejula guidance was lowered for fiscal 2018, the SITC data remains a key catalyst, Karnauskas tells investors in a research note. She believes Lynparza approval likely in first line gBRCA maintenance and reiterates a Buy rating on Tesaro with a $100 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.